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Role of sympathetic nerve inhibition and body sodium-volume
state in the antihypertensive action of clonidine in essential hyper-
tension. A simultaneous analysis of the interrelationships be-
tween mean blood pressure (MBP), plasma catecholamines,
plasma renin activity (PRA) and aldosterone, exchangeable body
sodium, and blood volume was carned out before and after acute
and chronic administration of clonidine in 15 patients with essen-
tial hypertension, in order to further elucidate the mechanism(s)
of action of this drug. After a single oral dose of 200 g, clonidine
produced a significant fall in MBP, heart rate, plasma norepi-
nephrine (NE), PRA, and aldosterone. There were significant
correlations (P <0.01) between NE and MBP, but not between
PRA or aldosterone and MBP both before and after the ingestion
of clonidine. Furthermore, there was a significant correlation (P
< 0.05) between the magnitude of the fall of plasma NE and
change in MBP. After 6 weeks of treatment, clonidine at a dose
of 960 80 ,ag/day produced a significant decrement in MBP and
NE, but not in PRA and aldosterone; with upright posture, the
magnitude of the fall in MBP was significantly greater (P <
0.01), and the rise in plasma NE was significantly smaller (P <
0.01) after chronic clonidine treatment. There was also a signifi-
cant fall (P <0.01) in exchangeable sodium and plasma volume.
The data provide evidence that inhibition of the sympathetic ner-
vous system by clonidine plays a major role and that the de-
crease in exchangeable body sodium and blood volume after
chronic treatment may contribute to the antihypertensive action
of the drug.
Roles de l'inhibition sympathique du bilan de sodium et du vol-
ume circulant dans l'action antihypertensive de Ia clonidine au
cours de l'hypertension essentielle. Une analyse simultanée des
relations entre La pression artérielle moyenne (MBP), les caté-
cholamines (NE), l'activité rénine (PRA), l'aldostérone plasma-
tiques, le sodium échangeable et le volume sanguin a été con-
duite avant et après l'administration aiguë et chronique de cloni-
dine a is malades atteints d'hypertension essentielle afin de
mieux élucider le mécanisme d'action de cette drogue. Après
une dose moyenne de 200 g par voie orale, Ia clonidine produit
une chute significative de MBP, du rythme cardiaque, de NE,
PRA et aldostérone plasmatiques. II existe une correlation sig-
nificative (P < 0,01) entre NE et MBP mais pas entre PRA ou
aldostérone et MBP aussi bien avant qu'après l'ingestion de
clonidine. De plus il existe une correlation significative (P <
0,05) entre l'importance de Ia chute de NE plasmatique et La
modification de MBP. Après six semaines de traitement ala dose
de 960 80 gIjour, Ia clonidine produit une chute significative
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de MBP et NE mais non de PRA et aldostérone. En ortho-
statisme Ia chute de MBP est significativement plus grande (P <
0,01) et l'augmentation de NE du plasma significativement plus
faible (P < 0,01) après un traitement prolongé. Ii est observe
aussi une baisse significative (P <0,01) du sodium échangeable
et du volume plasmatique. Ces résultats apportent Ia preuve de
ce que l'inhibition sympathique joue un role majeur et de ce que
la diminution du sodium échangeable et du volume sanguin peut
contribuer, au cours d'un traitement chronique, a I'action anti-
hypertensive de cette drogue.
Clonidine is an effective antihypertensive agent
[1-9]. The mechanisms underlying its blood pres-
sure lowering effect, however, are not fully under-
stood. Animal studies suggest that clonidine lowers
blood pressure through its effect on the central and
peripheral sympathetic nervous system [10—19].
Limited data in humans support such a contention.
A fall in urinary catecholamines was noted in pa-
tients with essential hypertension during treatment
with clonidine [20]. Furthermore, Louis et a! [21]
found a decrease in blood levels of norepinephrine
in six patients given an acute i.v. dose of clonidine.
Other studies have suggested the possibility that
clonidine may exert its effect by decreasing plasma
renin activity (PRA) [4, 22—24]. It is also possible
that clonidine mediates its action by altering total
body sodium and/or blood volume. Adequate data
on this issue are not available. A decrease in urinary
excretion of sodium was noted after acute adminis-
tration of clonidine [3, 4], but natriuresis reap-
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peared following several days of therapy [20]. In-
creased sodium excretion was noted in rats [25] and
in conscious [26] but not in anesthetized dogs [27]
during clonidine administration.
To study the relative contribution of the various
factors underlying the antihypertensive activity of
clonidine, we carried out simultaneous analysis of
the interrelationships between blood pressure,
plasma catecholamines, PRA and aldosterone, ex-
changeable body sodium and blood volume before
and after acute and chronic administration of the
drug in 15 patients with essential hypertension.
Methods
Fifteen patients with essential hypertension, 8
males and 7 females, were studied. Their ages
ranged between 30 and 51 (44 1.8 SEM) years.
Seven were caucasians; and eight, blacks. Patients
were included in the study only if their diastolic
blood pressure was found to be equal to or greater
than 100 mm Hg during three subsequent weekly
visits to the outpatient clinic. Patients with clinical
signs or history of congestive heart failure, ar-
rhythmia, cerebrovascular accidents, hypertensive
retinopathy grade III or IV (Keith-Wagener-Barker),
severe hypertension (greater than 125 mm Hg dia-
stolic), diabetes mellitus, liver disease, edema, renal
diseases or renal failure (creatinine clearance less
than 80 mllmin), cancer, asthma, gout, thyroid dys-
function, and women on oral contraceptive drugs
were excluded from the study. A diagnosis of sec-
ondary hypertension was adequately ruled out by
the finding of normal blood chemistry, urinalysis,
urinary catecholamines, chest x-ray, electrocardio-
gram, i.v. pyelography, and renal arteriography
when clinically indicated.
The patients were admitted to the Clinical Re-
search Center after an informed consent was ob-
tained. They were placed on a diet containing 120
mEq of sodium and 80 mEq of potassium for at least
6 days when their urinary sodium was equal to their
intake. On day 5, a dose of 8 pCi of sodium 22 was
given orally at 8:00 A.M., and a 24-hour urine collec-
tion was obtained. On the morning of day 6, the pa-
tients remained supine and fasting. Venous cath-
eters were inserted on both arms at 7:00 A.M. and
maintained patent with heparin solution. At 7:45
A.M., blood samples for the determinations of
plasma sodium, potassium, creatinine, norepineph-
rine (NE), epinephrine (E), dopamine, PRA, al-
dosterone, and sodium 22 were obtained. Measure-
ments of heart rate and blood pressure were made
in the supine position. At 8:00 A.M., approximately
5 pCi of 1251-human serum albumin was injected i.v.
in the arm contralateral to the one used for blood
drawing. Blood samples for determining of the plasma
concentration of iodine 125 were obtained at 10,
15, and 20 mm, thereafter. The subjects then as-
sumed the upright posture. Blood samples were ob-
tained, and determinations of heart rate and blood
pressure were made after 10mm of passive standing
and after an additional 50 mm of ambulation.
After completion of the measurements described
above, the patients received a light breakfast, and
approximately one-half hour later, returned to the
supine position. Blood pressure and pulse rate were
measured at 20-mm intervals for an hour. They then
received an oral dose of clonidine (200 pg). Mea-
surements of pulse rate and blood pressure were
made, and blood samples were obtained before and
30, 60, 120, 240, and 360 mm after administration of
clonidine. The patients were discharged with the in-
structions to adhere to the diet without added salt or
salty foods, and to take clonidine (100 g) three
times daily. Thereafter, patients were seen in the
outpatient clinic at weekly intervals for a period of 6
weeks. During this time, the dose of clonidine was
progressively increased until blood pressure de-
creased below 140/90 or intolerable side effects de-
veloped or a total dose of 1500 tgIday was reached.
The average dose of clonidine administered was 960
80 g'day (range, 300 to 1500 tg/day). During the
last 6 days of the chronic treatment period, the pa-
tients were readmitted to the Clinical Research
Center and kept on the 120-mEq sodium diet. At the
end of these 6 days, blood pressure, pulse rate, and
plasma catecholamines, aldosterone, and PRA were
determined at supine position, after 10 mm of pas-
sive standing and after an additional 50 mm of am-
bulation according to the protocol previously de-
scribed. Exchangeable sodium and plasma volume
were also measured. Of the 15 patients, 3 failed to
return for evaluation after 6 weeks of chronic treat-
ment. Therefore, it was possible to evaluate the ef-
fects of chronic administration of clonidine in only
12 patients.
Patients were classified in high, normal, or low
PRA according to our own nomogram constructed
from the relationship between PRA measured after
1 hour of ambulation and 24-hour urinary excretion
of sodium in 60 normal subjects.
Blood pressure was measured with an automatic
recorder (Physiometric SRII, Sphygmetrics Inc.,
Woodland Hills, California). Each data point of
blood pressure is the mean of three consecutive
readings. Mean blood pressure (MBP) was calcu-
lated as the sum of diastolic blood pressure and one
Clonidine in essential hypertension 353
third of pulse pressure. The concentrations of so-
dium and potassium in plasma and urine were dter-
mined by an Instrumentation Laboratory flame ho-
tometer and that of creatinine by a Technicon auto-
analyzer.
Plasma aldosterone was measured by radioimmu-
noassay [28], with a commercial kit (Diagnostic
Products Corporation, Los Angeles, California).
PRA was also measured by the radioimmunoassay
method of Sealey, Gerten-Banes, and Laragh [29],
with the antiserum provided by Endocrine Sciences
(Tarzana, California), the 1251-angiotensin I from
New England Nuclear (Boston, Massachusetts),
and the angiotensin I standard provided by Cal
Biomed (San Diego, California). The interassay co-
efficient of variability for aldosterone was 11.6%
(for 17 consecutive determinations), and the coeffi-
cient of variability for PRA was 7.3% (for 40 con-
secutive determinations).
Plasma catecholamines were measured in dupli-
cate by the radioenzymatic method of DaPrada and
Zurcher [30], with the enzyme catechol-o-methyl
transferase prepared according to the method of
Axelrod and Tomchick [31] and a methyl-donor 3H-
methyl-s-adenosine-methionine (New England Nu-
clear, Boston, Massachusetts). The sensitivity of
this method is 1 pg for norepinephrine and epineph-
rine and 5 pg for dopamine. This method is highly
specific. Among physiologic substances, only epi-
nm and 3-4-dihydroxyphenyl-glycol showed mini-
mal interference. Mean coefficient of intraassay and
control plasma variations in 78 unselected con-
secutive determinations with this method were
5.1% and 12.1% for plasma NE, 5.7 and 10.1% for
E, and 7.8 and 21.2% for dopamine.
Exchangeable sodium and plasma volume were
measured by radioisotope dilution techniques with
carrier-free sodium-22 chloride (New England Nu-
clear, Boston, Massachusetts) [32] and iodinated
(1251) -human serum albumin (Mallinckrodt, Saint
Louis, Missouri) [33]. The data were evaluated sta-
tistically by paired Student's t test and by regres-
sion analysis, and are expressed as the means
SEM.
Results
The acute effects of clonidine on MBP, pulse
rate, and blood levels of catecholamines, PRA, and
aldosterone are given in Table 1. The drug produced
a significant fall in MBP from 105 2.8 to 97 2.9
mm Hg (P < 0.01) after 120 mm of its administra-
tion; this effect was maintained for an additional 120
mm, and MBP returned to control values by 6 hours
after the administration of the drug. Pulse rate de-
creased simultaneously and remained significantly
below control values for the entire 6 hours of obser-
vation.
There was a significant decrease in plasma levels
of NE from 23.7 2.36 to 17.8 8.10 ng/dl (P <
0.01), which became apparent earlier than the drop
in MBP (Table 1). Plasma NE levels continued to
fall and reached a trough of 11.2 1.78 ng/dl by 4
hours after the ingestion of the drug and remained
low at a time when MBP returned to basal levels.
There was significant correlation (r = 0.71, P <
0.01) between basal plasma NE and MBP. Further-
more, there was a significant correlation between
the magnitude of the fall in plasma NE levels and
change in MBP (r = 0.58, P < 0.01) and the de-
crease in pulse rate (P < 0.01) after the administra-
tion of clonidine. The drug did not affect the blood
levels of epinephrine or dopamine.
There was no correlation between the basal levels
of PRA or aldosterone and MBP. The acute admin-
istration of clonidine produced a significant fall in
PRA and plasma aldosterone levels (Table 1), but
there was no correlation between the changes in
MBP and PRA or plasma aldosterone. When the pa-
tients were divided into two groups, those with
high-normal PRA and those with low PRA, no dif-
Table!. Acute effects of clonidine after a single oral dose of 200 g
Basal
Time, mm
30 60 120 240 360
Mean blood pressure, mm Hg
Pulse rate,beatslmin
Norepinephrine,ng/dl
Epinephrine,ng/dl
Dopaminengldl
PRA,ng/ml/hr
Aldosterone,ng/dl
105.0 2.80
81.0 2.80
23.7 2.36
1.9 0.34
9.7 1.87
4.5 1.00
15.5 1.21
104.0
78.0
22.1
2.2
9.8
3.7
12.9
2.90
2.50
2.50
0.40
1.96
0.76
1.19k
101.0
78.0
17.8
2.0
8.4
3.7
12.7
2.80
2.80
l.80
0.61
1.60
0.74
1.10
97.0 2.90a
70.0 2.80a
14.9 2.32
2.2 0.85
8.4 1.44
2.6 0.56a
12.2 0.61k
97.0
69.0
11.2
2.3
9.3
1.9
12.2
3.001
2.60a
l.78
0.89
2.10
0.41
1.08
104.0 3.10
71.0 3.00
13.2 1.99a
2.9 0.68
9.1 1.59
2.0 0.48
13.7 1.14
a P < 0.01.
I P < 0.05.
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Table 2. Acute effects of clonidine in hypertensive patients classified according to their PRAUNaV relationshipa
Basal
Time, mm
30 60 120 240 360
Norepinephrine
Normal PRA 24.0 3.36 22.6 3.30 18.0 2.70 16.0 3.10 12.0 2.39 14.0 2.80
LowPRA 23.0 2.74 21.0 3.73 17.0 1.55 13.0 2.33 10.0 2.70 12.0 2.20
Mean blood pressure
Normal PRA 105.0 3.60 103.0 3.70 101.0 3.70 97.0 3.90 97.0 2.70 102.0 2.40
Low PRA 104.0 4.90 104.0 5.20 107.0 4.70 97.0 3.80 98.0 7.80 108.0 8.30
PRA
Normal PRA 6.1 1.23 5.0 0.87 5.1 0.83 3.4 0.72 2.6 0.50 2.6 0.57
LowPRA 1.3 O.33' 1.1 0.20b 1.1 0•17b 1.1 0.24b 0.9 023b 0.7 0.24k'
Aldosterone
Normal PRA 14.0 1.00 12.0 1.10 13.0 1.57 13.0 0.80 10.0 1.20 13.0 2.30
LowPRA 19.0 2.40 15.0 1.96 13.0 0.96 11.0 0.92 16.0 l.88c 14.0 1.40
a Values are the means SEM. There were 10 patients with normal plasma renin activity (PRA) and 5 patients with low PRA.
P < 0.01.
P < 0.05.
ferences were found in the basal levels of NE, Fig. 1). PRA and plasma aldosterone were also re-
MBP, or in the degree of the changes in these pa- duced, but the differences were not significant.
rameters after clonidine administration (Table 2). The effects of chronic administration of clonidine
PRA decreased 57% in the high-normal PRA and on MBP, heart rate, plasma catecholamines, PRA,
46% in the low PRA group, and plasma aldosterone and aldosterone at the supine position, after upright
fell by 30% and 42%, respectively, posture, and following ambulation are given in
To exclude the possibility that the decreases in Table 3. After 6 weeks of treatment, clonidine at a
mean arterial pressure and plasma NE were due to dose of 960 80 gIday (range, 300 to 1500 /.Lglday)
prolonged bed rest and not to the drug, the effects of produced a significant decrease in the basal levels of
placebo and clonidine were compared in 4 patients. MBP, plasma NE and epinephrine, and heart rate in
The placebo was tested on day 5 of the research the 12 patients who completed the study. There
protocol. Plasma NE and mean blood pressure were were no significant changes in PRA or plasma al-
both significantly lower after clonidine (P < 0.05; dosterone. In 3 patients, MBP fell whereas PRA in-
creased.
Upright posture and ambulation was associated
I120
.1. -3 I
liD1-
I
I
I TIiDol-I90L
o-—.o Placebo
with a fall in MBP and a rise in heart rate, plasma
NE and aldosterone levels, and PRA (Table 3). The
magnitude of the fall in MBP was, however, signifi-
cantly greater (P <0.01) and the rise in plasma NE
was significantly smaller (P < 0.01) after chronic
clonidine treatment. The effects of chronic cloni-
dine treatment were not different among the pa-
Lu
0—oClonidine
20
c
0z
10
Time, rn/n
Fig. 1. Comparison between placebo and a single oral dose of
200 j.g of clonidine in four patients with essential hypertension
while resting supine. Mean blood pressure was significantly re-
duced (P < 0.05) at 120 through 360 mm whereas the reduction of
norepinephrme was significantly only at 360 mm (P < 0.05).
There were modest decrements in creatinine
tients with high PRA and those with low PRA.
clearance from 112 6.7 to 101 5.8 mllmin/1.73
m2 after 6 weeks of treatment with clonidine (P <
0.01). Exchangeable sodium and plasma volume
were significantly (P < 0.01) decreased from 36
1.5 to 32 1.3 mEq/kg and from 37 1.6 to 31
1.9 mllkg of body wt (Fig. 2).
Discussion
The results of the present study provide evidence
that inhibition of the sympathetic nervous system
by clonidine plays an important role in its anti-
hypertensive action. First, plasma levels of NE and
—60—30 0 60 120 240 360
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Table 3. Effects of 6 weeks of treatment with clonidine on plasma catecholamines, plasma aldosterone, heart rate, and plasma renin
activity (PRA)
All patients (N = 12)
Norepinephnne
ngldl
Epiriephrine
ngldl
Dopamine
ng/dl
Mean blood
pressure
mm Hg
Heart rate
beats/mm
PRA
ng/ml/hr
Aldosterone
ng/dl
Supine
Before 21 2.6 3.7 0.80 11 2.8 114 2.2 69 1.8 3.1 0.64 16 2.8
After 6 l.2' 1.1 0•16b 15 6.3 102 2.5 56 l.8' 2.0 0.53 14 1.2
Standing
Before 46 4.9 5.2 0.96 11 4.2 110 2.9 93 3.5 5.5 1.41 27 3.2
After 17 2.5' 2.3 0.74" 7 1.2 77 4.4" 81 5.5 2.9 0.84 19 1.7'
50-mm Ambulation
Before 50 6.5 5.7 0.99 12 4.3 105 2.4 96 5.2 6.5 1.5 41 3.8
After 19 25b 3.8 1.22 9 1.9 73 5.5" 83 4.5 4.1 1.09 32 2.7c
a Values are the means SCM.
"P < 0.01 compared to the values before treatment with clonidine.
P < 0.05 compared to the values before treatment with clonidine.
MBP decreased significantly and concomitantly
(Table 1) after the acute administration of 200 1ttg of
clonidine, and there was direct and significant rela-
tionship between these changes. Second, chronic
administration of the drug was associated with a fall
in plasma NE and MBP, and again, a significant cor-
relation was present between these two parameters.
E
_0
w
0
>-o
Finally, upright posture and ambulation after chron-
ic clonidine treatment was associated with a smaller
rise in plasma NE and a greater fall in MBP.
It is obvious, however, that other mechanisms
may be operative as well. Available data indicate
that the state of body sodiumlvolume plays a critical
role in the pathogenesis of hypertension [34-35],
and the decrease in exchangeable body sodium and
blood volume after chronic treatment may contrib-
ute to the antihypertensive action of the drug. Pre-
vious observations in humans [20] and in animals
[25—27] suggest that clonidine may increase urinary
sodium excretion, and such an effect may be re-
sponsible for the decrease in exchangeable sodium
and plasma volume. The mechanism(s) of such nat-
riuresis is unknown, but reduction in plasma levels
of aldosterone [24] and/or NE [36-38] may be con-
tributory.
Clonidine administration was also followed by a
decline in PRA and blood levels of aldosterone, and
these changes may have contributed to the effect of
the drug on blood pressure [4, 22-24]. Niarchos,
Baer, and Radichevich [23] found that the decrease
in MBP after treatment with clonidine of patients
with hypertension correlated with both the pre-
treatment level and the decrease in PRA after thera-
py. Their patient population was not, however, a
homogeneous group of patients with essential hy-
pertension, but included patients with renovascular
hypertension and those with parenchymal renal dis-
ease; the patients were also on low salt intake. In
these patients, an elevated PRA most probably
played a role in the elevation of blood pressure. Our
data on patients with essential hypertension and
who were receiving adequate sodium intake do not
support the notion that the decrease in PRA was a
major factor in the antihypertensive action of cloni-
Before After
Fig. 2. Exchangeable sodium and plasma volume before and af-
ter 6 weeks of treatment with clonidine. The decrements are Sig-
nificant (P < 0.01).
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dine. First, there was no correlation between the
decrease in PRA and the fall in MBP following both
the acute or chronic administration of clonidine.
Second, the decrease in MBP was not different
among the two groups of patients with low or nor-
mal-high PRA. Third, in 3 patients, MBP fell after
chronic clonidine treatment, whereas PRA in-
creased. Finally, it should be emphasized that Wing
et a! [38] reported a decrease in MBP after clonidine
in normotensive subjects who displayed an increase
in PRA during therapy. It appears that the role of
the decrease in PRA in the hypotensive action of
clonidine may depend on the state of body sodium
and/or on whether PRA has been playing a role in
the pathogenesis of the hypertension of the patients
receiving the drug.
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